欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (4): 390-396.doi: 10.12092/j.issn.1009-2501.2022.04.006

• 心血管疾病药物治疗最新研究进展 • 上一篇    下一篇

β2-微球蛋白的研究进展

张潇伊1,蒯铮1,邹云增2   

  1. 1复旦大学附属中山医院老年科,上海 200032;2复旦大学附属中山医院,上海市心血管病研究所,复旦大学生物医学研究所,上海 200032
  • 出版日期:2022-04-26 发布日期:2022-05-17
  • 通讯作者: 邹云增,男,博士,博士生导师,研究方向:心肌肥厚、高血压、心力衰竭。 E-mail: zou.yunzeng@zs-hospital.sh.cn
  • 作者简介:张潇伊,女,心血管专业博士,老年科主治医师,研究方向:心肌肥厚、高血压、心力衰竭。 E-mail: zhangjunava@163.com

Research progress of β2 microglobulin

ZHANG Xiaoyi1, KUAI Zheng1, ZOU Yunzeng2   

  1. 1 Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 2 Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China
  • Online:2022-04-26 Published:2022-05-17

摘要: β2-微球蛋白(β2-MG)是主要组织相容性复合体类的关键成分I分子,帮助细胞毒性t淋巴细胞(CTL)免疫反应。血清中β2-MG的含量与多种疾病动态相关。大多数对β2-MG的研究主要集中在肾病、肿瘤、淀粉样原纤维的发病机制,而近些年有研究发现其还参与了心血管系统不良预后、衰老认知障碍、抗菌方面的作用。该文章总结近些年β2-MG的国内外研究,提出β2-MG可能在人体中多系统发挥作用以及其可能的药物分子靶向应用前景。

关键词: β2-微球蛋白, 心血管系统, 衰老

Abstract: β2 microglobulin (β2-MG) is a key component I molecule of the major histocompatibility complex class that assists in the cytotoxic T lymphocyte (CTL) immune response. Serum β2-MG content is dynamically correlated with many diseases. Most studies on β2-MG mainly focus on the pathogenesis of kidney disease, tumor and amyloid fibrils. In recent years, some studies have found that β2-MG is also involved in the adverse prognosis of cardiovascular system, cognitive impairment of aging and antibacterial effects. This paper summarized the domestic and foreign studies on β2-MG in recent years, and proposed the possible role of β2-MG in multi-system human body and its potential application prospect of drug molecular targeting.

Key words: β2 microglobulin, cardiovascular system, senium

中图分类号: